Long-term progression-free survival of apatinib monotherapy for relapsed ovarian cancer: a case report and literature review

• Main Authors: Zhang D, Huang J, Sun Y, Guo Q
• Format: Article
• Language: English
• Published: Dove Medical Press 2019-05-01
• Series: OncoTargets and Therapy
• Subjects: : ovarian cancer; apatinib monotherapy; anti-angiogenic therapy; vascular endothelial growth factor receptor
• Online Access: https://www.dovepress.com/long-term-progression-free-survival-of-apatinib-monotherapy-for-relaps-peer-reviewed-article-OTT

Di Zhang,1,2 Jiaqi Huang,1,2 Yulan Sun,2 Qisen Guo11Shandong Cancer Hospital Affiliated to Shandong University, Shandong University, Jinan 250117, People’s Republic of China; 2Shandong Academy of Medical Sciences, Shandong Cancer Hospital and Institute, Shandong Cancer Hospital affiliated to Shandong University, Jinan 250117, People’s Republic of ChinaAbstract: Ovarian cancer is the deadliest gynecologic malignancy, which poses a great threat to female health. Anti-angiogenic therapy could bring clinical benefit for patients with ovarian cancer. Apatinib, an oral small-molecule vascular endothelial growth factor receptor-2 inhibitor, has shown notable therapeutic effect in a wide variety of tumors. We report a woman with advanced ovarian cancer who received apatinib at 250 mg/day after failure of multiple-line treatment regimens, followed by discussion through review of literature. The patient has quite a long progression-free survival time of 24 months, with a satisfactory quality of life. Apatinib monotherapy may provide an additional option for advanced ovarian cancer，but it still needs further observation and exploration.Keywords: ovarian cancer, apatinib monotherapy, anti-angiogenic therapy, vascular endothelial growth factor receptor